Chun‐wa Chung
GlaxoSmithKline (United Kingdom)(GB)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Ubiquitin and proteasome pathways, Histone Deacetylase Inhibitors Research, Peptidase Inhibition and Analysis
Most-Cited Works
- → Suppression of inflammation by a synthetic histone mimic(2010)1,563 cited
- → Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia(2011)1,506 cited
- → A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response(2012)940 cited
- → Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation(2015)734 cited
- → Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation(2020)416 cited
- → Biophysics in drug discovery: impact, challenges and opportunities(2016)366 cited
- → Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains(2011)334 cited
- → Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains(2013)302 cited
- → Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition(2015)231 cited
- → Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)(2012)207 cited